® Plus Rituximab in Indolent Non-Hodgkin's Lymphomas Presented at ASH" />
Celgene Corporation
Dec 7, 2010
Add to Briefcase

Clinical Data from Two Phase II Studies Evaluating REVLIMID® Plus Rituximab in Indolent Non-Hodgkin's Lymphomas Presented at ASH

BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) --

Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the combination of REVLIMID® (lenalidomide) plus rituximab in indolent non-Hodgkin's lymphoma (NHL) were presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL.

In the first study, treatment with lenalidomide and low-dose dexamethasone plus rituximab was evaluated in patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma previously resistant to rituximab. The Phase II study demonstrated an average 58% (14/24) overall response rate (ORR), with median follow-up of 13.3 months (3.1-28.8). Responses by specific cancer subtype ranged from 67% (2/3) ORR in patients with small lymphocytic lymphoma, 60% (9/15) ORR in patients with follicular lymphoma, and 60% (3/5) ORR in patients with mantle cell lymphoma.

In the study, 27 patients received two 28-day cycles of lenalidomide and low-dose dexamethasone, after which their response was assessed. Patients then received a single course of 4 weekly doses of rituximab during cycle 3 of treatment, while treatment with lenalidomide and dexamethasone continued. Stable and responding patients continued treatment with lenalidomide and dexamethasone until disease progression or development of toxicity.

Following the lenalidomide and dexamethasone induction phase, 29% (7/24) of patients achieved a partial response (PR) or better.

In the study, the most common grade 3 or 4 non-haematologic adverse events were hypokalemia (4 patients), neutropenia (10), hypophosphatemia (4), hypokalemia (4) and pneumonia (3). Tumour flare occurred in one patient. There were two deaths during protocol therapy: one due to myocarditis during the induction phase, and one due to lymphoma in a patient removed from the study due to grade 3 rash, which subsequently resolved.

In the second study, the combination of lenalidomide and rituximab was evaluated in patients with relapsed or refractory indolent NHL with measurable disease who had received at least one prior therapy.

Eighteen patients were enrolled in the study, including 14 with follicular lymphoma, two with marginal zone lymphoma and two with chronic lymphocytic leukemia/small lymphocytic lymphoma. Patients were given 25 mg of lenalidomide on days 1-21 of a 28-day cycle, continuing until disease progression. Patients also received rituximab 375 mg/m2 IV on day 15 of cycle 1, repeated weekly for a total of four doses.

Of the 17 patients evaluable for response, the ORR was 76% (13/17), which included 41% of patients (7/17) with a CR and 35% (6/17) patients with a PR. Additionally, 11% (2/17) of patients had stable disease. At a median follow-up of 25 months, the median progression-free survival (PFS) for all evaluable patients was 12.4 months.

As all seven patients who achieved a CR had follicular lymphoma, the study further evaluated whether follicular lymphoma patients with a certain genetic polymorphism at position 158 of the FcyRIIIa gene, which replaces either a phenylalanine (F) or valine (V) at the site, had a higher objective response and PFS compared to patients without this polymorphism. Patients with the V/V subtype (n=1) had a 100% ORR, patients with the V/F subtype (n=6) had a 100% ORR, and patients with the F/F subtype had an 80% ORR. PFS for V/V patients could not be calculated due to the small number of patients. Median PFS was 14.9 months for V/F patients and 12.4 months for F/F patients.

In the study, the most common grade 3 or 4 toxicities were lymphopenia (24% 4/17), neutropenia (24% 4/17), fatigue (24% 4/17) and hyponatremia (12% 2/17). After two of the first four patients developed grade 3 tumor lysis syndrome, the protocol was amended to reduce the lenalidomide starting dose to 20 mg, and prophylaxis with allopurinol was initiated.

These data are from investigational studies. REVLIMID does not have marketing approval for the treatment of patients with B-cell lymphoma or mantle cell lymphoma previously resistant to rituximab.


REVLIMID® is an IMiDs® compound. REVLIMID and other IMiDs continue to be evaluated in over 100 clinical trials. The IMiDs pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions, including composition-of- matter and use patents.

REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle-East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand.

REVLIMID is also approved in the Americas, the Middle-East and Asia for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Marketing Authorization Applications are currently being evaluated in a number of other countries.

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma (MM) patients who have received at least one prior therapy.

REVLIMID is indicated for patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Important Safety Information


Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or death to a developing baby. In women of childbearing potential, obtain 2 negative pregnancy tests before starting REVLIMID treatment. Women of childbearing potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment. To avoid fetal exposure to lenalidomide, REVLIMID is only available under a restricted distribution program called "RevAssist®."

Information about the RevAssist program is available at www.REVLIMID.com or by calling the manufacturer's toll-free number 1-888-423-5436.


REVLIMID can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q MDS had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q MDS should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors. (see DOSAGE and ADMINISTRATION)


REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with MM who were treated with REVLIMID and dexamethasone therapy. Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID may lessen the potential for venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of an individual patient's underlying risk factors.


Pregnancy Category X:

Allergic Reactions:


Fetal Risk:

Reproductive Risk and Special Prescribing Requirements (RevAssist Program):

Hematologic Toxicity--Multiple Myeloma:

Deep Vein Thrombosis:

Allergic Reactions:

Tumor Lysis Syndrome:

Tumor Flare Reaction:



Nursing Mothers:

Geriatric Use:

Renal Impairment:


Multiple Myeloma

Myelodysplastic Syndromes


Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

About Mantle-Cell Lymphoma

MCL is one of several subtypes of NHL and results from a malignant transformation of a B lymphocyte in the mantle zone - the outer edge of the lymph node follicles. The uncontrolled growth of the transformed lymphocytes, or lymphoma cells, cause tumors to form in the lymph nodes, which then become enlarged. Lymphoma cells can also spread to other tissues, such as the marrow, liver and gastrointestinal tract.

MCL is distinguished from other subtypes of B-cell lymphoma by abnormal expression of cyclin D1, a protein that stimulates cell growth. Approximately 85 percent of MCL cases are caused by genetic changes involving the cyclin D1 gene on chromosome 11 and chromosome 14.

About Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control. The Company's actual results, performance, or achievements could be materially different from those projected by these forward-looking statements.The factors that could cause actual results, performance, or achievements to differ from the forward-looking statements are discussed in the Company's filings with the Securities and Exchange Commission, such as the Company's Form 10-K, 10-Q and 8-K reports.Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements.

SOURCE: Celgene International Sàrl

Celgene International Sàrl
Kevin Loth, Director of External Relations
+41 32 729 86 21